Patents by Inventor Andrew Simon Bell
Andrew Simon Bell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240108624Abstract: The invention provides a compound of formula (I), or pharmaceutically acceptable ester, amide, carbamate, solvate or salt thereof, including a salt of such an ester, amide or carbamate, wherein R1 is an optionally substituted phenyl, or an optionally substituted 5- or 6-membered aromatic heterocycle; and R2 is an optionally substituted 5- or 6-membered aromatic heterocycle. Also provided are pharmaceutical compositions comprising a compound of formula (I).Type: ApplicationFiled: September 8, 2023Publication date: April 4, 2024Applicants: EXSCIENTIA LTD.,, EVOTEC INTERNATIONAL GMBHInventors: Andrew Simon BELL, Adrian Michael SCHREYER, Stephanie VERSLUYS
-
Publication number: 20230382911Abstract: The present invention provides compounds of formula I or II: wherein X1, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.Type: ApplicationFiled: July 28, 2023Publication date: November 30, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Andrew Simon BELL, Jérémy BESNARD, Anthony Richard BRADLEY, Luke GREEN, Wolfgang HAAP, Buelent KOCER, Andreas KUGLSTATTER, Xavier LUCAS, Patrizio MATTEI, Dmitry MAZUNIN, Claus RIEMER, Willem Paul VAN HOORN
-
Patent number: 11786528Abstract: The invention provides a compound of formula (I), or pharmaceutically acceptable ester, amide, carbamate, solvate or salt thereof, including a salt of such an ester, amide or carbamate, wherein R1 is an optionally substituted phenyl, or an optionally substituted 5- or 6-membered aromatic heterocycle; and R2 is an optionally substituted 5- or 6-membered aromatic heterocycle. Also provided are pharmaceutical compositions comprising a compound of formula (I).Type: GrantFiled: June 4, 2019Date of Patent: October 17, 2023Assignees: EXSCIENTIA LTD., EVOTEC INTERNATIONAL GMBHInventors: Andrew Simon Bell, Adrian Michael Schreyer, Stephanie Versluys
-
Publication number: 20230227449Abstract: The present invention provides compounds of formula I or II: wherein X1, X3, R1, R2, R3, R4 and R5 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.Type: ApplicationFiled: December 19, 2022Publication date: July 20, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Andrew Simon Bell, Jérémy Besnard, Anthony Richard Bradley, Luke Green, Wolfgang Haap, Buelent Kocer, Andreas Kuglstatter, Xavier Lucas, Patrizio Mattei, Dmitry Mazunin, Hasane Ratni, Claus Riemer, Willem Paul Van Hoorn
-
Publication number: 20230219953Abstract: The present invention provides compounds of formula I wherein X1, X2, X3, X4, R1, R1a, R1b, R2?, R2?, R3?, R3?, R6 and R7 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.Type: ApplicationFiled: December 19, 2022Publication date: July 13, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Andrew Simon Bell, Jérémy Besnard, Anthony Richard Bradley, Luke Green, Wolfgang Haap, Buelent Kocer, Andreas Kuglstatter, Xavier Lucas, Patrizio Mattei, Dmitry Mazunin, Claus Riemer, Willem Paul Van Hoorn
-
Publication number: 20230008875Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.Type: ApplicationFiled: August 17, 2022Publication date: January 12, 2023Applicant: Sumitomo Pharma Co., Ltd.Inventors: Hidefumi YOSHINAGA, Yohei IKUMA, Junya IKEDA, Satoshi ADACHI, Harunobu MITSUNUMA, Yoshinori AIHARA, Jeremy BESNARD, Andrew Simon BELL
-
Publication number: 20220411431Abstract: This invention provides compounds of formula (I) and salts thereof, which have activity as inhibitors of N-myristoyl transferase (NMT). The invention also relates to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect, including protozoan infections (such as malaria and leishmaniasis), viral infections (such as human rhinovirus and HIV), and hyperproliferative disorders (such as B-cell lymphoma).Type: ApplicationFiled: July 27, 2022Publication date: December 29, 2022Applicant: Imperial College Innovations LimitedInventors: Andrew Simon Bell, Edward William Tate, Robin John Leatherbarrow, Jennie Ann Hutton, James Antony Brannigan
-
Patent number: 11466011Abstract: This invention provides compounds of formula (I) and salts thereof, which have activity as inhibitors of N-myristoyl transferase (NMT). The invention also relates to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect, including protozoan infections (such as malaria and leishmaniasis), viral infections (such as human rhinovirus and HIV), and hyperproliferative disorders (such as B-cell lymphoma).Type: GrantFiled: July 8, 2020Date of Patent: October 11, 2022Assignee: IMPERIAL COLLEGE INNOVATIONS LIMITEDInventors: Andrew Simon Bell, Edward William Tate, Robin John Leatherbarrow, Jennie Ann Hutton, James Antony Brannigan
-
Patent number: 11466007Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.Type: GrantFiled: July 22, 2019Date of Patent: October 11, 2022Assignee: SUMITOMO PHARMA CO., LTD.Inventors: Hidefumi Yoshinaga, Yohei Ikuma, Junya Ikeda, Satoshi Adachi, Harunobu Mitsunuma, Yoshinori Aihara, Jeremy Besnard, Andrew Simon Bell
-
Publication number: 20220213079Abstract: The present invention relates to a compound represented by formula (1): the compound having antagonist activity against serotonin 5-HT2A receptors and serotonin 5-HT7 receptors; or a pharmaceutically acceptable salt of the compound. (In the formula, Z is a nitrogen atom and the like; Y is carbonyl and the like; m and n are 1 and the like; R1a through R1d, R2a through R2d, and R4a through R4d are a hydrogen atom and the like; R3 is alkyl and the like; and Q is a specific bicyclic group.Type: ApplicationFiled: December 23, 2020Publication date: July 7, 2022Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Yuki FUJII, Masayuki SAKUMA, Yoshinori AIHARA, Jeremy BESNARD, Andrew Simon BELL
-
Patent number: 11339151Abstract: The present invention relates to a compound represented by formula (1): the compound having antagonist activity against serotonin 5-HT2A receptors and serotonin 5-HT7 receptors; or a pharmaceutically acceptable salt of the compound. (In the formula, Z is a nitrogen atom and the like; Y is carbonyl and the like; m and n are 1 and the like; R1a through R1d, R2a through R2d, and R4a through R4d are a hydrogen atom and the like; R3 is alkyl and the like; and Q is a specific bicyclic group.Type: GrantFiled: November 17, 2021Date of Patent: May 24, 2022Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Yuki Fujii, Masayuki Sakuma, Yoshinori Aihara, Jeremy Besnard, Andrew Simon Bell
-
Publication number: 20220073506Abstract: The present invention relates to a compound represented by formula (1): the compound having antagonist activity against serotonin 5-HT2A receptors and serotonin 5-HT7 receptors; or a pharmaceutically acceptable salt of the compound. (In the formula, Z is a nitrogen atom and the like; Y is carbonyl and the like; m and n are 1 and the like; R1a through R1d, R2a through R2d, and R4a through R4d are a hydrogen atom and the like; R3 is alkyl and the like; and Q is a specific bicyclic group.Type: ApplicationFiled: November 17, 2021Publication date: March 10, 2022Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Yuki FUJII, Masayuki SAKUMA, Yoshinori AIHARA, Jeremy BESNARD, Andrew Simon BELL
-
Publication number: 20220064158Abstract: The invention provides inter alia compound as defined herein and its use in the prevention or treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect, e.g. cancer.Type: ApplicationFiled: December 19, 2019Publication date: March 3, 2022Applicant: IMPERIAL COLLEGE INNOVATIONS LIMITEDInventors: Edward William TATE, Andrew Simon BELL
-
Publication number: 20210251995Abstract: The invention provides a compound of formula (I), or pharmaceutically acceptable ester, amide, carbamate, solvate or salt thereof, including a salt of such an ester, amide or carbamate, wherein R1 is an optionally substituted phenyl, or an optionally substituted 5- or 6-membered aromatic heterocycle; and R2 is an optionally substituted 5- or 6-membered aromatic heterocycle. Also provided are pharmaceutical compositions comprising a compound of formula (I).Type: ApplicationFiled: June 4, 2019Publication date: August 19, 2021Applicants: EXSCIENTIA LTD.,, EVOTEC INTERNATIONAL GMBHInventors: Andrew Simon BELL, Adrian Michael SCHREYER, Stephanie VERSLUYS
-
Publication number: 20210230169Abstract: The present invention relates to compounds and pharmaceutically acceptable salts or solvates thereof for use in the treatment or prevention of fascioliasis. Some of these compounds are novel per se and also have activity as inhibitors of Schistosoma growth. The invention also relates to pharmaceutical compositions comprising such novel compounds, salts or solvates and to the use of such novel compounds as medicaments, in particular in the treatment or prevention of schistosomiasis, also known as bilharzia.Type: ApplicationFiled: July 16, 2019Publication date: July 29, 2021Inventors: John Mark Francis Gardner, Andrew Simon Bell
-
Patent number: 11046700Abstract: The present invention relates to compounds of formula (1a), formula (1b), formula (1c) or formula (1d): or, or a pharmaceutically acceptable salt thereof, which have activity as inhibitors of Schistosoma growth. The invention also relates to pharmaceutical compositions comprising such compounds, salts or solvates and to the use of such compounds as medicaments, in particular in the treatment or prevention of schistosomiasis, also known as bilharzia.Type: GrantFiled: January 15, 2018Date of Patent: June 29, 2021Assignee: Merck Patent GmbHInventors: John Mark Francis Gardner, Andrew Simon Bell
-
Publication number: 20200339586Abstract: This invention provides compounds of formula (I) and salts thereof, which have activity as inhibitors of N-myristoyl transferase (NMT). The invention also relates to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect, including protozoan infections (such as malaria and leishmaniasis), viral infections (such as human rhinovirus and HIV), and hyperproliferative disorders (such as B-cell lymphoma).Type: ApplicationFiled: July 8, 2020Publication date: October 29, 2020Applicant: Imperial College Innovations LimitedInventors: Andrew Simon Bell, Edward William Tate, Robin John Leatherbarrow, Jennie Ann Hutton, James Antony Brannigan
-
Patent number: 10759804Abstract: This invention provides compounds of formula (I) and salts thereof, which have activity as inhibitors of N-myristoyl transferase (NMT). The invention also relates to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect, including protozoan infections (such as malaria and leishmaniasis), viral infections (such as human rhinovirus and HIV), and hyperproliferative disorders (such as B-cell lymphoma).Type: GrantFiled: June 29, 2016Date of Patent: September 1, 2020Assignee: IMPERIAL COLLEGE INNOVATIONS LIMITEDInventors: Andrew Simon Bell, Edward William Tate, Robin John Leatherbarrow, Jennie Ann Hutton, James Antony Brannigan
-
Patent number: 10745401Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.Type: GrantFiled: February 10, 2020Date of Patent: August 18, 2020Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Hidefumi Yoshinaga, Yohei Ikuma, Junya Ikeda, Satoshi Adachi, Harunobu Mitsunuma, Yoshinori Aihara, Jeremy Besnard, Andrew Simon Bell
-
Publication number: 20200255432Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.Type: ApplicationFiled: July 22, 2019Publication date: August 13, 2020Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Hidefumi YOSHINAGA, Yohei IKUMA, Junya IKEDA, Satoshi ADACHI, Harunobu MITSUNUMA, Yoshinori AIHARA, Jeremy BESNARD, Andrew Simon BELL
